Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ischemic Heart Disease

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 187 articles:
HTML format
Text format



Single Articles


    March 2017
  1. LOU B, Gao H, Zhou C
    Remote ischemic conditioning in ST-segment elevation myocardial infarction: Effect of coronary collateral circulation.
    Am Heart J. 2017;185:e1.
    PubMed     Text format    


  2. NAKANISHI K, Jin Z, Homma S, Elkind MS, et al
    Left ventricular mass-geometry and silent cerebrovascular disease: The Cardiovascular Abnormalities and Brain Lesions (CABL) study.
    Am Heart J. 2017;185:85-92.
    PubMed     Text format     Abstract available


  3. BAVISHI C, Sardar P, Chatterjee S, Khan AR, et al
    Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: Meta-analysis of randomized trials.
    Am Heart J. 2017;185:26-34.
    PubMed     Text format     Abstract available


  4. LEE H, Koo BK, Park KW, Shin ES, et al
    A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary arte
    Am Heart J. 2017;185:17-25.
    PubMed     Text format     Abstract available


  5. KHETAN A, Purushothaman R, Zullo M, Gupta R, et al
    Rationale and design of a cluster-randomized controlled trial to evaluate the effects of a community health worker-based program for cardiovascular risk factor control in India.
    Am Heart J. 2017;185:161-172.
    PubMed     Text format     Abstract available


  6. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Acute coronary syndrome quality improvement in Kerala (ACS QUIK): Rationale and design for a cluster-randomized stepped-wedge trial.
    Am Heart J. 2017;185:154-160.
    PubMed     Text format     Abstract available


  7. YUSUF S, Joseph P
    The epidemic of cardiovascular disease in South Asians: Time for action.
    Am Heart J. 2017;185:150-153.
    PubMed     Text format    


    February 2017
  8. VARENHORST C, Johnston N
    RE: Letter to the editor, Dr Cheng et al. "Smartphone apps and secondary prevention after myocardial infarction-How can long-term usage be improved?"
    Am Heart J. 2017;184:e2.
    PubMed     Text format    


  9. CHENG K, Oswal A
    Smartphone apps and secondary prevention after myocardial infarction - How can long-term usage be improved?
    Am Heart J. 2017;184:e1.
    PubMed     Text format    


  10. ARMSTRONG PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, et al
    Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898].
    Am Heart J. 2017;184:157.
    PubMed     Text format    


  11. WELSH RC, Roe MT, Steg PG, James S, et al
    Corrigendum to "A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease" [Am Heart J 181 (2016) 92-100].
    Am Heart J. 2017;184:156.
    PubMed     Text format    


  12. NEWMAN JD, Rockman CB, Kosiborod M, Guo Y, et al
    Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease.
    Am Heart J. 2017;184:114-120.
    PubMed     Text format     Abstract available


  13. ERNE P, Iglesias JF, Urban P, Eberli FR, et al
    Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
    Am Heart J. 2017;184:106-113.
    PubMed     Text format     Abstract available


  14. VOORA D, Coles A, Lee KL, Hoffmann U, et al
    An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.
    Am Heart J. 2017;184:133-140.
    PubMed     Text format     Abstract available


  15. COFFENG JK, van der Ploeg HP, Castellano JM, Fernandez-Alvira JM, et al
    A 30-month worksite-based lifestyle program to promote cardiovascular health in middle-aged bank employees: Design of the TANSNIP-PESA randomized controlled trial.
    Am Heart J. 2017;184:121-132.
    PubMed     Text format     Abstract available


    January 2017
  16. SHERWOOD A, Smith PJ, Hinderliter AL, Georgiades A, et al
    Effects of exercise and stress management training on nighttime blood pressure dipping in patients with coronary heart disease: A randomized, controlled trial.
    Am Heart J. 2017;183:85-90.
    PubMed     Text format     Abstract available


  17. LU Y, Zhou S, Dreyer RP, Caulfield M, et al
    Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study.
    Am Heart J. 2017;183:74-84.
    PubMed     Text format     Abstract available


  18. ZETTLER ME, Peterson ED, McCoy LA, Effron MB, et al
    Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events a
    Am Heart J. 2017;183:62-68.
    PubMed     Text format     Abstract available


  19. BOCCARA F, Miantezila Basilua J, Mary-Krause M, Lang S, et al
    Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy.
    Am Heart J. 2017;183:91-101.
    PubMed     Text format     Abstract available


  20. VENKATESH BA, Nauffal V, Noda C, Fujii T, et al
    Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network "Patients with Intermittent Claudication Injected with ALDH Bright Cel
    Am Heart J. 2017;183:24-34.
    PubMed     Text format     Abstract available


  21. RIMAC G, Fearon WF, De Bruyne B, Ikeno F, et al
    Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis.
    Am Heart J. 2017;183:1-9.
    PubMed     Text format     Abstract available


    December 2016
  22. AU YEUNG SL, Lin SL, Lam HS, Schooling CM, et al
    Effect of l-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine on ischemic heart disease risk: A Mendelian randomization study.
    Am Heart J. 2016;182:54-61.
    PubMed     Text format     Abstract available


  23. RODRIGUEZ F, Lin S, Maron DJ, Knowles JW, et al
    Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines.
    Am Heart J. 2016;182:97-102.
    PubMed     Text format     Abstract available


  24. BABER U, Dangas G, Cohen DJ, Gibson CM, et al
    Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
    Am Heart J. 2016;182:125-134.
    PubMed     Text format     Abstract available


  25. GRODZINSKY A, Arnold SV, Wang TY, Sharma P, et al
    Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
    Am Heart J. 2016;182:111-118.
    PubMed     Text format     Abstract available


  26. HARRISON RW, Radhakrishnan V, Lam PS, Allocco DJ, et al
    Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2016;182:103-110.
    PubMed     Text format     Abstract available


  27. LEE JM, Cho DK, Hahn JY, Song YB, et al
    Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet The
    Am Heart J. 2016;182:1-8.
    PubMed     Text format     Abstract available


    November 2016
  28. YAKSH A, Kik C, Knops P, van Ettinger MJ, et al
    Early, de novo atrial fibrillation after coronary artery bypass grafting: Facts and features.
    Am Heart J. 2016;184:62-70.
    PubMed     Text format     Abstract available


  29. WELSH RC, Roe MT, Steg PG, James S, et al
    A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
    Am Heart J. 2016;181:92-100.
    PubMed     Text format     Abstract available


  30. VEROUHIS D, Sorensson P, Gourine A, Henareh L, et al
    Effect of remote ischemic conditioning on infarct size in patients with anterior ST-elevation myocardial infarction.
    Am Heart J. 2016;181:66-73.
    PubMed     Text format     Abstract available


  31. PICCARO DE OLIVEIRA P, Gonzales V, Lopes RD, Schmidt MM, et al
    Serious infections among unselected patients with ST-elevation myocardial infarction treated with contemporary primary percutaneous coronary intervention.
    Am Heart J. 2016;181:52-59.
    PubMed     Text format     Abstract available


  32. MONDESIR FL, Brown TM, Muntner P, Durant RW, et al
    Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS).
    Am Heart J. 2016;181:43-51.
    PubMed     Text format     Abstract available


  33. RERUP SA, Bang LE, Mogensen UM, Engstrom T, et al
    The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction.
    Am Heart J. 2016;181:35-42.
    PubMed     Text format     Abstract available


  34. DERY JP, Mehta SR, Fisher HN, Zhang X, et al
    Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTud
    Am Heart J. 2016;181:26-34.
    PubMed     Text format     Abstract available


  35. WILDI K, Nelles B, Twerenbold R, Rubini Gimenez M, et al
    Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction.
    Am Heart J. 2016;181:16-25.
    PubMed     Text format     Abstract available


  36. VIRANI SS, Akeroyd JM, Ramsey DJ, Chan WJ, et al
    Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act.
    Am Heart J. 2016;181:74-82.
    PubMed     Text format     Abstract available


  37. VALENTINO M, Al Danaf J, Panakos A, Ragupathi L, et al
    Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Am Heart J. 2016;181:130-136.
    PubMed     Text format     Abstract available


  38. FERRI LA, Morici N, Grosseto D, Tortorella G, et al
    A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Am Heart J. 2016;181:101-106.
    PubMed     Text format     Abstract available


    October 2016
  39. WINDECKER S, Tijssen J, Giustino G, Guimaraes AH, et al
    Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Am Heart J. 2016;184:81-87.
    PubMed     Text format     Abstract available


  40. SHAH R, Yow E, Jones WS, Kohl LP 3rd, et al
    Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.
    Am Heart J. 2016;184:1-9.
    PubMed     Text format     Abstract available


  41. ALLEN JE, Knight S, McCubrey RO, Bair T, et al
    beta-blocker dosage and outcomes after acute coronary syndrome.
    Am Heart J. 2016;184:26-36.
    PubMed     Text format     Abstract available


  42. MCCARTHY CP, McEvoy JW
    The narrative review on morphine in acute coronary syndrome: Recognizing opioidergic cardioprotection-reply.
    Am Heart J. 2016;180:e7-8.
    PubMed     Text format    


  43. RUAN X, Chiravuri S, Kaye AD
    The narrative review on morphine in acute coronary syndrome: Recognizing opioidergic cardioprotection.
    Am Heart J. 2016;180:e5-6.
    PubMed     Text format    


  44. SRA S, Tan MK, Mehta SR, Fisher HN, et al
    Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.
    Am Heart J. 2016;180:82-9.
    PubMed     Text format     Abstract available


  45. LEMKES JS, Janssens GN, Straaten HM, Elbers PW, et al
    Coronary angiography after cardiac arrest: Rationale and design of the COACT trial.
    Am Heart J. 2016;180:39-45.
    PubMed     Text format     Abstract available


  46. NGUYEN TL, Phan J, Hogan J, Hee L, et al
    Adverse diastolic remodeling after reperfused ST-elevation myocardial infarction: An important prognostic indicator.
    Am Heart J. 2016;180:117-27.
    PubMed     Text format     Abstract available


  47. SUMMERS MR, Menon V
    Insights from cardiac imaging after ST-elevation myocardial infarction: Will increased recognition of patients at risk translate into improved long-term outcomes?
    Am Heart J. 2016;180:113-6.
    PubMed     Text format    


  48. KONTOS MC, Wang TY, Chen AY, Bates ER, et al
    The effect of high-risk ST elevation myocardial infarction transfer patients on risk-adjusted in-hospital mortality: A report from the American Heart Association Mission: Lifeline program.
    Am Heart J. 2016;180:74-81.
    PubMed     Text format     Abstract available


  49. GIBSON CM, Korjian S, Tricoci P, Daaboul Y, et al
    Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute
    Am Heart J. 2016;180:22-8.
    PubMed     Text format     Abstract available


    September 2016
  50. TROXEL AB, Asch DA, Mehta SJ, Norton L, et al
    Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program.
    Am Heart J. 2016;179:166-74.
    PubMed     Text format     Abstract available


  51. MCNEELY C, Markwell S, Vassileva CM
    Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.
    Am Heart J. 2016;179:195-203.
    PubMed     Text format     Abstract available


  52. TANGUTURI VK, Wasfy JH
    Hospital readmissions after percutaneous coronary intervention aredeclining, but caution ahead is needed.
    Am Heart J. 2016;179:192-4.
    PubMed     Text format    


  53. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    PubMed     Text format     Abstract available


  54. CHANG M, Ahn JM, Kim N, Lee PH, et al
    Complete versus incomplete revascularization in patients with multivessel coronary artery disease treated with drug-eluting stents.
    Am Heart J. 2016;179:157-65.
    PubMed     Text format     Abstract available


  55. BHATNAGAR A, Bolli R, Johnstone BH, Traverse JH, et al
    Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.
    Am Heart J. 2016;179:142-50.
    PubMed     Text format     Abstract available


  56. HAO Y, Liu J, Liu J, Smith SC Jr, et al
    Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome.
    Am Heart J. 2016;179:107-15.
    PubMed     Text format     Abstract available


  57. DE WAHA A, Sandner S, von Scheidt M, Boening A, et al
    A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Inve
    Am Heart J. 2016;179:69-76.
    PubMed     Text format     Abstract available


    August 2016
  58. ABATE E, Hoogslag GE, Al Amri I, Debonnaire P, et al
    Time course, predictors, and prognostic implications of significant mitral regurgitation after ST-segment elevation myocardial infarction.
    Am Heart J. 2016;178:115-25.
    PubMed     Text format     Abstract available


  59. HARRISON RW, Simon D, Miller AL, de Lemos JA, et al
    Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;178:95-101.
    PubMed     Text format     Abstract available


  60. JOHNSTON N, Bodegard J, Jerstrom S, Akesson J, et al
    Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study.
    Am Heart J. 2016;178:85-94.
    PubMed     Text format     Abstract available


  61. SUTTON NR, Li S, Thomas L, Wang TY, et al
    The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked dat
    Am Heart J. 2016;178:65-73.
    PubMed     Text format     Abstract available


  62. DECKER C, Garavalia L, Garavalia B, Gialde E, et al
    Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention.
    Am Heart J. 2016;178:190-7.
    PubMed     Text format     Abstract available


  63. ROTHBERG MB, Martinez KA
    Risky business: Personalizing the approach to percutaneous coronary intervention.
    Am Heart J. 2016;178:185-7.
    PubMed     Text format    


  64. ARMAGANIJAN LV, Alexander KP, Huang Z, Tricoci P, et al
    Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2016;178:176-84.
    PubMed     Text format     Abstract available


  65. SELKER HP, Harris WS, Rackley CE, Marsh JB, et al
    Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes: Biological mechanisms for benefit in the IMMEDIATE Trial.
    Am Heart J. 2016;178:168-75.
    PubMed     Text format     Abstract available


  66. RIDKER PM, Amarenco P, Brunell R, Glynn RJ, et al
    Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Eve
    Am Heart J. 2016;178:135-44.
    PubMed     Text format     Abstract available


  67. KAUL P, Ohman EM, Knight JD, Anstrom KJ, et al
    Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary
    Am Heart J. 2016;178:55-64.
    PubMed     Text format     Abstract available


  68. CAMARO C, Damen SA, Brouwer MA, Kedhi E, et al
    Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Am Heart J. 2016;178:37-44.
    PubMed     Text format     Abstract available


  69. RAO C, Du J, Li X, Li J, et al
    Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Se
    Am Heart J. 2016;178:9-18.
    PubMed     Text format     Abstract available


  70. AKERBLOM A, Clare RM, Lokhnygina Y, Wallentin L, et al
    Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.
    Am Heart J. 2016;178:1-8.
    PubMed     Text format     Abstract available


    July 2016
  71. DOLL JA, Wang TY, Choudhry NK, Cannon CP, et al
    Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarct
    Am Heart J. 2016;177:33-41.
    PubMed     Text format     Abstract available


  72. TING R, Tejpal A, Finken L, Fisher M, et al
    Repatriation to referral hospital after reperfusion of STEMI patients transferred for primary percutaneous coronary intervention: Insights of a Canadian regional STEMI care system.
    Am Heart J. 2016;177:145-52.
    PubMed     Text format     Abstract available


  73. REN S, Hure A, Peel R, D'Este C, et al
    Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE).
    Am Heart J. 2016;177:58-65.
    PubMed     Text format     Abstract available


  74. DELGADO-LISTA J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, et al
    CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a low-fat
    Am Heart J. 2016;177:42-50.
    PubMed     Text format     Abstract available


  75. CHUN S, Choi Y, Chang Y, Cho J, et al
    Sugar-sweetened carbonated beverage consumption and coronary artery calcification in asymptomatic men and women.
    Am Heart J. 2016;177:17-24.
    PubMed     Text format     Abstract available


  76. NDREPEPA G, Iijima R, Kufner S, Braun S, et al
    Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.
    Am Heart J. 2016;177:9-16.
    PubMed     Text format     Abstract available


  77. SHIMADA YJ, Bansilal S, Wiviott SD, Becker RC, et al
    Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Am Heart J. 2016;177:1-8.
    PubMed     Text format     Abstract available


    June 2016
  78. GRIMFJARD P, Erlinge D, Koul S, Lagerqvist B, et al
    Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report.
    Am Heart J. 2016;176:78-82.
    PubMed     Text format     Abstract available


  79. BLUMENTHAL JA, Feger BJ, Smith PJ, Watkins LL, et al
    Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial.
    Am Heart J. 2016;176:53-62.
    PubMed     Text format     Abstract available


  80. PATTI G, Cavallari I
    Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials.
    Am Heart J. 2016;176:36-43.
    PubMed     Text format     Abstract available


  81. GONZALEZ HM, Tarraf W, Rodriguez CJ, Gallo LC, et al
    Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS/SOL) results.
    Am Heart J. 2016;176:134-44.
    PubMed     Text format     Abstract available


  82. JOUNI H, Askew JW, Crusan DJ, Miller TD, et al
    Temporal trends of single-photon emission computed tomography myocardial perfusion imaging in patients without prior coronary artery disease: A 22-year experience at a tertiary academic medical center.
    Am Heart J. 2016;176:127-33.
    PubMed     Text format     Abstract available


  83. VENTURA HO, Lavie CJ
    Tackling cardiovascular disease in Hispanic/Latinos: Achieving 2020 Goals.
    Am Heart J. 2016;176:125-6.
    PubMed     Text format    


  84. MCCARTHY CP, Mullins KV, Sidhu SS, Schulman SP, et al
    The on- and off-target effects of morphine in acute coronary syndrome: A narrative review.
    Am Heart J. 2016;176:114-21.
    PubMed     Text format     Abstract available


  85. PURI R, Nissen SE, Somaratne R, Cho L, et al
    Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Am Heart J. 2016;176:83-92.
    PubMed     Text format     Abstract available


  86. DE LUCA L, Capranzano P, Patti G, Parodi G, et al
    Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.
    Am Heart J. 2016;176:44-52.
    PubMed     Text format     Abstract available


  87. VAN DER HEIJDEN LC, Kok MM, Danse PW, Schramm AR, et al
    Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.
    Am Heart J. 2016;176:28-35.
    PubMed     Text format     Abstract available


  88. LOPES RD, de Paola AA, Lorga Filho AM, Consolim-Colombo FM, et al
    Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study.
    Am Heart J. 2016;176:10-6.
    PubMed     Text format     Abstract available


  89. ANDERSON LL, Dai D, Miller AL, Roe MT, et al
    Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;176:1-9.
    PubMed     Text format     Abstract available


    May 2016
  90. VAN DIJK PR, Mouden M, Hermanides R
    Directions for future trials on blood glucose-lowering drugs to improve left ventricular function post-ST-segment elevation myocardial infarction.
    Am Heart J. 2016;175:e1.
    PubMed     Text format    


  91. XU H, Li W, Yang J, Wiviott SD, et al
    The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China.
    Am Heart J. 2016;175:193-201.
    PubMed     Text format     Abstract available


  92. SILVERMAN MG, Morrow DA
    Hospital triage of acute myocardial infarction: Is admission to the coronary care unit still necessary?
    Am Heart J. 2016;175:172-4.
    PubMed     Text format    


  93. PILGRIM T, Vranckx P, Valgimigli M, Stefanini GG, et al
    Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
    Am Heart J. 2016;175:56-65.
    PubMed     Text format     Abstract available


  94. ERLINGE D, Koul S, Eriksson P, Schersten F, et al
    Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial).
    Am Heart J. 2016;175:36-46.
    PubMed     Text format     Abstract available


  95. WEBER B, Bersch-Ferreira AC, Torreglosa CR, Ross-Fernandes MB, et al
    Corrigendum to 'The Brazilian Cardioprotective Nutritional Program to reduce events and risk factors in secondary prevention for cardiovascular disease: study protocol (The BALANCE Program Trial)' [American Heart Journal 171/1 (2016) 73-81].
    Am Heart J. 2016;175:202-203.
    PubMed     Text format    


  96. VAN DIEPEN S, Lin M, Bakal JA, McAlister FA, et al
    Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units?
    Am Heart J. 2016;175:184-92.
    PubMed     Text format     Abstract available


  97. PARSH J, Seth M, Briguori C, Grossman P, et al
    The optimal definition of contrast-induced acute kidney injury for prediction of inpatient mortality in patients undergoing percutaneous coronary interventions.
    Am Heart J. 2016;175:160-7.
    PubMed     Text format     Abstract available


  98. ARBEL Y, Qiu F, Bennell MC, Austin PC, et al
    Association between publication of appropriate use criteria and the temporal trends in diagnostic angiography in stable coronary artery disease: A population-based study.
    Am Heart J. 2016;175:153-9.
    PubMed     Text format     Abstract available


  99. REED BN, Fox ER, Konig M, Jackevicius CA, et al
    The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action.
    Am Heart J. 2016;175:130-41.
    PubMed     Text format     Abstract available


  100. HUISMAN J, van der Heijden LC, Kok MM, Danse PW, et al
    Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).
    Am Heart J. 2016;175:121-9.
    PubMed     Text format     Abstract available


  101. ALLEN NB, Lloyd-Jones D, Hwang SJ, Rasmussen-Torvik L, et al
    Genetic loci associated with ideal cardiovascular health: A meta-analysis of genome-wide association studies.
    Am Heart J. 2016;175:112-20.
    PubMed     Text format     Abstract available


  102. DOBSON LE, Fairbairn TA, Musa TA, Uddin A, et al
    Sex-related differences in left ventricular remodeling in severe aortic stenosis and reverse remodeling after aortic valve replacement: A cardiovascular magnetic resonance study.
    Am Heart J. 2016;175:101-11.
    PubMed     Text format     Abstract available


  103. SHAFIQ A, Arnold SV, Gosch K, Kureshi F, et al
    Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: Insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study.
    Am Heart J. 2016;175:94-100.
    PubMed     Text format     Abstract available


  104. SIDEBOTTOM AC, Sillah A, Miedema MD, Vock DM, et al
    Changes in cardiovascular risk factors after 5 years of implementation of a population-based program to reduce cardiovascular disease: The Heart of New Ulm Project.
    Am Heart J. 2016;175:66-76.
    PubMed     Text format     Abstract available


  105. SHIMADA YJ, Cannon CP, Liu Y, Wilson C, et al
    Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care
    Am Heart J. 2016;175:18-27.
    PubMed     Text format     Abstract available


  106. MATHEWS R, Fonarow GC, Li S, Peterson ED, et al
    Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines.
    Am Heart J. 2016;175:1-8.
    PubMed     Text format     Abstract available


    April 2016
  107. RANCHORD AM, Spertus JA, Buchanan DM, Gosch KL, et al
    Initiation of beta-blocker therapy and depression after acute myocardial infarction.
    Am Heart J. 2016;174:37-42.
    PubMed     Text format     Abstract available


  108. KOHL LP, Leimberger JD, Chiswell K, Jones WS, et al
    Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial.
    Am Heart J. 2016;174:7-13.
    PubMed     Text format     Abstract available


  109. LEE DS, Husain M, Wang X, Austin PC, et al
    Cardiovascular outcomes after pharmacologic stress myocardial perfusion imaging.
    Am Heart J. 2016;174:138-46.
    PubMed     Text format     Abstract available


  110. POVSIC TJ, Roe MT, Ohman EM, Steg PG, et al
    A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Am Heart J. 2016;174:120-8.
    PubMed     Text format     Abstract available


  111. HOLMAN RR, Bethel MA, George J, Sourij H, et al
    Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
    Am Heart J. 2016;174:103-10.
    PubMed     Text format     Abstract available


  112. ZIMERMAN A, Lopes RD, Stebbins AL, Guimaraes PO, et al
    Pooled analysis of adverse event collection from 4 acute coronary syndrome trials.
    Am Heart J. 2016;174:60-7.
    PubMed     Text format     Abstract available


  113. BENSENOR IM, Goulart AC, Santos IS, Bittencourt MS, et al
    Association between a healthy cardiovascular risk factor profile and coronary artery calcium score: Results from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Am Heart J. 2016;174:51-9.
    PubMed     Text format     Abstract available


  114. HENDRIKS SH, van Dijk PR, van Hateren KJ, van Pelt JL, et al
    High-sensitive troponin T is associated with all-cause and cardiovascular mortality in stable outpatients with type 2 diabetes (ZODIAC-37).
    Am Heart J. 2016;174:43-50.
    PubMed     Text format     Abstract available


  115. LIKOSKY DS, Zhang M, Paone G, Collins J, et al
    Impact of institutional culture on rates of transfusions during cardiovascular procedures: The Michigan experience.
    Am Heart J. 2016;174:1-6.
    PubMed     Text format     Abstract available


  116. GARGIULO G, Costa F, Ariotti S, Biscaglia S, et al
    Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Am Heart J. 2016;174:95-102.
    PubMed     Text format     Abstract available


  117. GUIMARAES PO, Sun JL, Kragholm K, Shah SH, et al
    Association of standard clinical and laboratory variables with red blood cell distribution width.
    Am Heart J. 2016;174:22-8.
    PubMed     Text format     Abstract available


    March 2016
  118. ACHARJEE S, Teo KK, Jacobs AK, Hartigan PM, et al
    Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial.
    Am Heart J. 2016;173:108-17.
    PubMed     Text format     Abstract available


  119. VAVALLE JP, van Diepen S, Clare RM, Hochman JS, et al
    Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes.
    Am Heart J. 2016;173:57-66.
    PubMed     Text format     Abstract available


  120. GRANDI SM, Eisenberg MJ, Joseph L, O'Loughlin J, et al
    Cessation treatment adherence and smoking abstinence in patients after acute myocardial infarction.
    Am Heart J. 2016;173:35-40.
    PubMed     Text format     Abstract available


  121. UEDA H, Kido A, Matsuhisa S, Asawa K, et al
    Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial.
    Am Heart J. 2016;173:134-42.
    PubMed     Text format     Abstract available


  122. LU J, Bagai A, Buller C, Cheema A, et al
    Incidence and characteristics of inappropriate and false-positive cardiac catheterization laboratory activations in a regional primary percutaneous coronary intervention program.
    Am Heart J. 2016;173:126-33.
    PubMed     Text format     Abstract available


  123. SABATINE MS, Giugliano RP, Keech A, Honarpour N, et al
    Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
    Am Heart J. 2016;173:94-101.
    PubMed     Text format     Abstract available


  124. O'BRIEN EC, Wu J, Schulte PJ, Christian A, et al
    Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease.
    Am Heart J. 2016;173:27-34.
    PubMed     Text format     Abstract available


  125. MAGNONI M, Andreini D, Gorini M, Moccetti T, et al
    Coronary atherosclerosis in outlier subjects at the opposite extremes of traditional risk factors: Rationale and preliminary results of the Coronary Atherosclerosis in outlier subjects: Protective and novel Individual Risk factors Evaluation (CAPIRE)
    Am Heart J. 2016;173:18-26.
    PubMed     Text format     Abstract available


  126. LEE G, Twerenbold R, Tanglay Y, Reichlin T, et al
    Clinical benefit of high-sensitivity cardiac troponin I in the detection of exercise-induced myocardial ischemia.
    Am Heart J. 2016;173:8-17.
    PubMed     Text format     Abstract available


  127. BRIGUORI C, Visconti G, Donahue M, De Micco F, et al
    RenalGuard system in high-risk patients for contrast-induced acute kidney injury.
    Am Heart J. 2016;173:67-76.
    PubMed     Text format     Abstract available


  128. VASSALLI G, Klersy C, De Servi S, Galatius S, et al
    Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial.
    Am Heart J. 2016;173:1-7.
    PubMed     Text format     Abstract available


    February 2016
  129. BUCHOLZ EM, Beckman AL, Krumholz HA, Krumholz HM, et al
    Excess weight and life expectancy after acute myocardial infarction: The obesity paradox reexamined.
    Am Heart J. 2016;172:173-81.
    PubMed     Text format     Abstract available


  130. THIELE H, Desch S, Piek JJ, Stepinska J, et al
    Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial.
    Am Heart J. 2016;172:160-9.
    PubMed     Text format     Abstract available


  131. EISEN A, Giugliano RP, Ruff CT, Nordio F, et al
    Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myoc
    Am Heart J. 2016;172:144-51.
    PubMed     Text format     Abstract available


  132. CALAIS F, Lagerqvist B, Leppert J, James SK, et al
    Thrombus aspiration in patients with large anterior myocardial infarction: A Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia trial substudy.
    Am Heart J. 2016;172:129-34.
    PubMed     Text format     Abstract available


  133. LIU Y, Chen JY, Huo Y, Ge JB, et al
    Aggressive hydraTion in patients with ST-Elevation Myocardial infarction undergoing Primary percutaneous coronary intervention to prevenT contrast-induced nephropathy (ATTEMPT): Study design and protocol for the randomized, controlled trial, the ATTEM
    Am Heart J. 2016;172:88-95.
    PubMed     Text format     Abstract available


  134. SEBBEN JC, Pinto Ribeiro DR, Lopes RD, de Winter R, et al
    The role of diabetes mellitus in the composition of coronary thrombi in patients presenting with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Am Heart J. 2016;172:26-33.
    PubMed     Text format     Abstract available


  135. WANG TY, McCoy LA, Bhatt DL, Rao SV, et al
    Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction.
    Am Heart J. 2016;172:9-18.
    PubMed     Text format     Abstract available


  136. DASARI TW, Hamilton S, Chen AY, Wang TY, et al
    Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR).
    Am Heart J. 2016;172:1-8.
    PubMed     Text format     Abstract available


  137. O'BRIEN EC, Thomas LE
    Untangling the paradox: Obesity as prognostic marker in prevalent cardiovascular disease.
    Am Heart J. 2016;172:170-2.
    PubMed     Text format    


  138. YAGGI HK, Mittleman MA, Bravata DM, Concato J, et al
    Reducing cardiovascular risk through treatment of obstructive sleep apnea: 2 methodological approaches.
    Am Heart J. 2016;172:135-43.
    PubMed     Text format     Abstract available


  139. SARA JD, Lennon RJ, Gulati R, Singh M, et al
    Utility of the Framingham Risk Score in predicting secondary events in patients following percutaneous coronary intervention: A time-trend analysis.
    Am Heart J. 2016;172:115-28.
    PubMed     Text format     Abstract available


  140. DIDIER R, Gaglia MA Jr, Koifman E, Kiramijyan S, et al
    Cerebrovascular accidents after percutaneous coronary interventions from 2002 to 2014: Incidence, outcomes, and associated variables.
    Am Heart J. 2016;172:80-7.
    PubMed     Text format     Abstract available


  141. PESARO AE, Granger CB, Lopes RD
    Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?
    Am Heart J. 2016;172:42-4.
    PubMed     Text format    


    January 2016
  142. BAINEY KR, Norris C, Shavadia J
    Response to: Letter to the Editor regarding the manuscript "Symptomatic graft failure and impact on clinical outcome after coronary artery bypass grafting surgery: Results from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Di
    Am Heart J. 2016;171:e11.
    PubMed     Text format    


  143. JAEGER C, Wildi K, Twerenbold R, Reichlin T, et al
    One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I.
    Am Heart J. 2016;171:92-102.
    PubMed     Text format     Abstract available


  144. KIM EK, Choi JH, Song YB, Hahn JY, et al
    A protective role of early collateral blood flow in patients with ST-segment elevation myocardial infarction.
    Am Heart J. 2016;171:56-63.
    PubMed     Text format     Abstract available


  145. WARREN J, Mehran R, Baber U, Xu K, et al
    Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI)
    Am Heart J. 2016;171:40-7.
    PubMed     Text format     Abstract available


  146. POKORNEY SD, Radder C, Schulte PJ, Al-Khatib SM, et al
    High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction.
    Am Heart J. 2016;171:25-32.
    PubMed     Text format     Abstract available


  147. EYUBOGLU M
    Preoperative diagnosis and postoperative prognosis in patients undergoing coronary artery bypass graft surgery.
    Am Heart J. 2016;171:e9.
    PubMed     Text format    


  148. JONES WS, Patel MR, Tsai TT, Shetterly SM, et al
    Response to Letter to the Editor regarding "Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization".
    Am Heart J. 2016;171:e7.
    PubMed     Text format    


  149. HERTZBERG D, Sartipy U, Holzmann MJ
    Letter in response to "Assessing the association of diabetes mellitus with acute kidney injury after coronary artery bypass grafting" by Fu-Shan Xue et al.
    Am Heart J. 2016;171:e3.
    PubMed     Text format    


  150. XUE FS, Liu GP, Li RP
    Assessing the association of diabetes mellitus with acute kidney injury after coronary artery bypass grafting.
    Am Heart J. 2016;171:e1-2.
    PubMed     Text format    


  151. WEBER B, Bersch-Ferreira AC, Torreglosa CR, Ross-Fernandes MB, et al
    The Brazilian Cardioprotective Nutritional Program to reduce events and risk factors in secondary prevention for cardiovascular disease: study protocol (The BALANCE Program Trial).
    Am Heart J. 2016;171:73-81.
    PubMed     Text format     Abstract available


  152. ZEITLER EP, Al-Khatib SM, Drozda JP Jr, Kessler LG, et al
    Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet).
    Am Heart J. 2016;171:64-72.
    PubMed     Text format     Abstract available


  153. SHAH R, Rogers KC, Matin K, Askari R, et al
    An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention.
    Am Heart J. 2016;171:14-24.
    PubMed     Text format     Abstract available


  154. KOLLURI R, Plessa AL, Sanders MC, Singh NK, et al
    A randomized study of the safety and efficacy of fondaparinux versus placebo in the prevention of venous thromboembolism after coronary artery bypass graft surgery.
    Am Heart J. 2016;171:1-6.
    PubMed     Text format     Abstract available


  155. EYUBOGLU M
    Clinical outcomes in patients with lower extremity peripheral artery disease undergoing revascularization.
    Am Heart J. 2016;171:e5.
    PubMed     Text format    


    December 2015
  156. CHANDRASEKHAR J, Mastoris I, Baber U, Sartori S, et al
    Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry.
    Am Heart J. 2015;170:1234-42.
    PubMed     Text format     Abstract available


  157. SACKS NC, Ash AS, Ghosh K, Rosen AK, et al
    Trends in acute myocardial infarction hospitalizations: Are we seeing the whole picture?
    Am Heart J. 2015;170:1211-9.
    PubMed     Text format     Abstract available


  158. CHEN R, Strait KM, Dharmarajan K, Li SX, et al
    Hospital variation in admission to intensive care units for patients with acute myocardial infarction.
    Am Heart J. 2015;170:1161-9.
    PubMed     Text format     Abstract available


  159. SPENCER FA, Sekercioglu N, Prasad M, Lopes LC, et al
    Culprit vessel versus immediate complete revascularization in patients with ST-segment myocardial infarction-a systematic review.
    Am Heart J. 2015;170:1133-9.
    PubMed     Text format     Abstract available


  160. PRATI F, Romagnoli E, Limbruno U, Pawlowski T, et al
    Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: The COCTAIL II trial.
    Am Heart J. 2015;170:1116-23.
    PubMed     Text format     Abstract available


  161. MEYERS HP, Limkakeng AT Jr, Jaffa EJ, Patel A, et al
    Validation of the modified Sgarbossa criteria for acute coronary occlusion in the setting of left bundle branch block: A retrospective case-control study.
    Am Heart J. 2015;170:1255-64.
    PubMed     Text format     Abstract available


  162. NICHOLS WW, Denardo SJ, Davidson JB, Huo T, et al
    Association of aortic stiffness and wave reflections with coronary flow reserve in women without obstructive coronary artery disease: An ancillary study from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation
    Am Heart J. 2015;170:1243-54.
    PubMed     Text format     Abstract available


  163. BOYDEN TF, Joynt KE, McCoy L, Neely ML, et al
    Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan.
    Am Heart J. 2015;170:1227-33.
    PubMed     Text format     Abstract available


  164. ESTES EH, Zhang ZM, Li Y, Tereshchenko LG, et al
    Individual components of the Romhilt-Estes left ventricular hypertrophy score differ in their prediction of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study.
    Am Heart J. 2015;170:1220-6.
    PubMed     Text format     Abstract available


  165. DANIELS LB, Clopton P, deFilippi CR, Sanchez OA, et al
    Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA).
    Am Heart J. 2015;170:1170-83.
    PubMed     Text format     Abstract available


  166. AULIN J, Siegbahn A, Hijazi Z, Ezekowitz MD, et al
    Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
    Am Heart J. 2015;170:1151-60.
    PubMed     Text format     Abstract available


  167. CELANO CM, Millstein RA, Bedoya CA, Healy BC, et al
    Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis.
    Am Heart J. 2015;170:1105-15.
    PubMed     Text format     Abstract available


  168. BERTRAND ME, Ferrari R, Remme WJ, Simoons ML, et al
    Perindopril and beta-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
    Am Heart J. 2015;170:1092-8.
    PubMed     Text format     Abstract available


  169. DASARI TW, Saucedo JF, Krim S, Alkhouli M, et al
    Clinical characteristics and in hospital outcomes of heart transplant recipients with allograft vasculopathy undergoing percutaneous coronary intervention: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2015;170:1086-91.
    PubMed     Text format     Abstract available


  170. KOHSAKA S, Miyata H, Ueda I, Masoudi FA, et al
    An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KiCS).
    Am Heart J. 2015;170:1077-85.
    PubMed     Text format     Abstract available


    November 2015
  171. DUDEK D, Dziewierz A, Widimsky P, Bolognese L, et al
    Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myo
    Am Heart J. 2015;170:1025-1032.
    PubMed     Text format     Abstract available


  172. RENTROP KP, Feit F
    Reperfusion therapy for acute myocardial infarction: Concepts and controversies from inception to acceptance.
    Am Heart J. 2015;170:971-80.
    PubMed     Text format     Abstract available


  173. RAO SV, Zeymer U, Douglas PS, Al-Khalidi H, et al
    A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial
    Am Heart J. 2015;170:929-37.
    PubMed     Text format     Abstract available


  174. BRANDON STACEY R, Leaverton PE, Schocken DD, Peregoy JA, et al
    Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis.
    Am Heart J. 2015;170:923-8.
    PubMed     Text format     Abstract available


  175. SCHWALM JD, Ivers NM, Natarajan MK, Taljaard M, et al
    Cluster randomized controlled trial of Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI).
    Am Heart J. 2015;170:903-13.
    PubMed     Text format     Abstract available


  176. DOLL JA, Hellkamp A, Thomas L, Ho PM, et al
    Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction.
    Am Heart J. 2015;170:855-64.
    PubMed     Text format     Abstract available


  177. CHEN WR, Hu SY, Chen YD, Zhang Y, et al
    Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Am Heart J. 2015;170:845-54.
    PubMed     Text format     Abstract available


  178. KO MJ, Park CM, Kim YJ, Kang SH, et al
    Clinical application and potential effects of 2014 hypertension guidelines on incident cardiovascular events.
    Am Heart J. 2015;170:1042-1049.
    PubMed     Text format     Abstract available


  179. CHEW DP, Astley CM, Luker H, Alprandi-Costa B, et al
    A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS).
    Am Heart J. 2015;170:995-1004.
    PubMed     Text format     Abstract available


  180. QADERDAN K, Ishak M, Heestermans AA, de Vrey E, et al
    Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70years and older-rationale and design of the POPular AGE study.
    Am Heart J. 2015;170:981-985.
    PubMed     Text format     Abstract available


  181. HERTZBERG D, Sartipy U, Holzmann MJ
    Type 1 and type 2 diabetes mellitus and risk of acute kidney injury after coronary artery bypass grafting.
    Am Heart J. 2015;170:895-902.
    PubMed     Text format     Abstract available


  182. CANTOR WJ, Mehta SR, Yuan F, Dzavik V, et al
    Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial.
    Am Heart J. 2015;170:880-6.
    PubMed     Text format     Abstract available


  183. COHEN MG, Matthews R, Maini B, Dixon S, et al
    Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience.
    Am Heart J. 2015;170:872-9.
    PubMed     Text format     Abstract available


  184. GOTBERG M, Christiansen EH, Gudmundsdottir I, Sandhall L, et al
    Instantaneous Wave-Free Ratio versus Fractional Flow Reserve guided intervention (iFR-SWEDEHEART): Rationale and design of a multicenter, prospective, registry-based randomized clinical trial.
    Am Heart J. 2015;170:945-50.
    PubMed     Text format     Abstract available


    September 2015
  185. LINDHOLM D, Storey RF, Christersson C, Halvorsen S, et al
    Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr.
    Am Heart J. 2015;170:465-70.
    PubMed     Text format     Abstract available


  186. PONTONE G, Patel MR, Hlatky MA, Chiswell K, et al
    Rationale and design of the Prospective LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts study.
    Am Heart J. 2015;170:438-46.
    PubMed     Text format     Abstract available


    August 2015
  187. HUNG RK, Al-Mallah MH, Qadi MA, Shaya GE, et al
    Cardiorespiratory fitness attenuates risk for major adverse cardiac events in hyperlipidemic men and women independent of statin therapy: The Henry Ford ExercIse Testing Project.
    Am Heart J. 2015;170:390-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: